MigraineNCT06633484
BIOMIGA: Results From Magnetic Resonance Imaging
An observational study of Migraine, run by Universitätsklinikum Hamburg-Eppendorf at 3 sites in 3 countries.
Trial summary
The projects comprising in the multicenter BIOMIGA project have been preregistered earlier with ID NTC04503083 at clinicaltrials.gov. Here the imaging subproject within the overall BIOMIGA aims is specified. Read more about this study
- Who is it for?
- Ages 25 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Migraine
- What is being tested?
- functional magnetic resonance imaging
- How many people
- 219 participants
- Where
- 3 sitesin 3 countries
- Study dates
- 15 Jan 2021to 1 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: Migraine patients and Healthy controls. The healthy controls where recruited among hospital staff and non-related acquaintances of the patients. All migraine patients enrolled in the study have been treated with CGRP-targeting mABs according to the indications approved by the respective National regulatory bodies(Germany, Spain, Italy).
Who may be able to join
- Migraine patients
- Adults between 25 and 55 years of age of both sexes;
- Patients diagnosed with high-frequency migraine (HFM) 8 or more migraine days/month) or CM with or without aura (>15 headache days migraine/month, of which 8 have migraine characteristics) according to the International Classification of Headache Disorders, 3rd edition, (ICHD-3);
- Females had to be postmenopausal for at least one year, surgically sterile or otherwise incapable of pregnancy, or using an acceptable method of birth control.
- Healthy controls
- Adults between 25 and 55 years of age of both sex;
- Absence of any past, or first-degree familial history of recurrent primary or secondary headache disorders.
Who cannot join
- For the clinical population:
- Headache on more than 25 days/month in the last 3 months;
- Medication overuse according to the ICHD-3 criteria.
- For the entire study population (migraine and healthy controls)
- Presence of any other significant medical condition (neurological disorders, severe psychiatric illness or cardiovascular disease);
- Evidence of drug, smoking or alcohol abuse or dependence within 12 months prior to V1, based on medical records or patient self-report. An alcohol consumption >100g/week will be considered as an abuse;
Show all 9Show fewer
- Pregnant or breastfeeding women;
- Women of childbearing potential, defined as all women physiologically capable of becoming pregnant who are not on contraception;
- Concomitant use of other migraine preventive drugs that may interfere with the endpoints of the study.
Trial locations and contacts
3 sites in 3 countries.
3 sites in 3 countries
About this study
Official title: BIOmarkers of MIGraine: a Proof of Concept Study on the Stratification of Responders to CGRP Monoclonal Antibodies - Results From Magnetic Resonance Imaging
The projects comprising in the multicenter BIOMIGA project have been preregistered earlier with ID NTC04503083 at clinicaltrials.gov. Here the imaging subproject within the overall BIOMIGA aims is specified. The hypotheses for this subproject of the magnetic resonance imaging part is based on hypotheses generating analyses of the data from one site (Hamburg, Germany) of this three-center study. At all three sites healthy controls and migraine patients underwent identical protocols with 3 types of magnetic resonance imaging including structural scans (MPRAGE), resting-state functional magnetic resonance imaging (rs-fMRI) as well as arterial spin labeling (ASL) with matched protocols across sites. Data was acquired before CGRP-antibody administration (day 1) and 12 weeks afterwards (day 2). We analyzed the data from one site (Hamburg, Germany) as hypotheses generating, published these data as a poster and aim to validate our results with the not-yet analyzed data from the two other sites (Pavia, Italy and Barcelona, Spain).
Read the detailed description
The Hamburg data was processed as stated below and will be used as independent data set for hypotheses generation. The data of the two other sites (Italy and Spain) will be processed identically to the Hamburg data set:
rs-FMRI
Preprocessing of the resting-state functional MR data followed the SPM12 pipeline (https://www.fil.ion.ucl.ac.uk/spm/software/spm12/) using slice time correction, realignment, coregistration to the structural image, normalization into MNI space, and smoothing with an 8mm^3 Gausian kernel. Data was further analyzed using the CONN-toolbox (https://web.conn-toolbox.org/) where a 0.003-0.08 Hz temporal filter and denoising with linear regression of confounding effects (white matter, CSF, movement) and linear detrending. We choose:
- Local Homogeneity (LCOR),
- Global Correlations (GCOR),
- Seed-Based Correlations (SBC): Seed to voxel and ROI to ROI with an additional mask of the hypothalamus
- Independent Component Analyses (group-ICA),
- Amplitude of Low-Frequency Fluctuations (ALFF)
Statistical comparisons calculated are defined as primary and secondary outcomes below and include (i) prediction of treatment outcome (reduction in headache days) from T0 (further PR), (ii) alterations between T0 and T1, (iii) differences between healthy controls and migraine patients at T0 (further HvsPAT), and (iv) differences between responders and non-responder at T0 and T1.
In the hypothesis generating Hamburg data significant results at a threshold of cluster-wise FDR-corrected p<0.05 with an entry threshold of voxel-wise uncorrected p<0.001, when corrected for age and sex in were found:
- LCOR: PR: Two clusters in left lateral occipital cortex and right temporal fusiform cortex; HvsPAT: bilateral thalamus left frontal operculum.
- SBC Seed to Voxel: PR: Hypothalamus 2 clusters, Sensori Motor Lateral R 1 cluster, Visula Lateral L 1 cluster, Visual Lateral R 3 cluster; HvsPAT: Sensori Motor Lateral L 5 cluster, Sensori Motor Lateral R 1 cluster, Sensori Motor Superior 3 cluster, Visual Medial 3 cluster, Visual Occipital 1 cluster, Visual Lateral L 4 cluster, Visual Lateral R 1 cluster,
- ICA: ICA 5 2 cluster, ICA 16 2 cluster, ICA 28 1 cluster, ICA 34 2 cluster; HvsPAT: ICA 4 3cluster, ICA 6 4 cluster, ICA 14 4 cluster, ICA 18 2 cluster, ICA 27 3 cluster, ICA 29 14 cluster, ICA 33 3 cluster, ICA 36 7 cluster, ICA 38 6 cluster
- There were no significant results for SBC ROI to ROI, GCOR and ALFF
- There were no significant results for the chosen threshold for the comparisons between responders and non-responder at T0 and T1 Preliminary results for local and global connectivity were recently presented at a scientific conference.
To reproduce the significant results from the Hamburg data there is choosen a small volume-corrected threshold of p<0.05. For non-significant result, the statistical threshold for the data of the two other sites will be set to voxel-wise FWE-corrected p<0.05.
MPRAGE Raw T1-images (aka MPRAGE) were processed using the CAT12-toolbox (https://neuro-jena.github.io/cat12-help/) which extents SPM12 (https://www.fil.ion.ucl.ac.uk/spm/software/spm12/). For controls and migraine patients with data from only the first day, images segmented into compartments of gray and white matter and normalized. For patients with data from 2 days, data was longitudinally segmented. Images of gray and white matter were smoothed with an isotropic Gaussian kernel of 6 mm3. T-test and F-tests implemented in the SPM12 toolbox were used to estimate significant differences at a threshold of cluster-wise-correct p<0.05. The individual total intracranial volume (TIV), which is also estimated by the CAT12-toolbox, was used as covariate to control for different brain sizes. Age and gender were used as further covariates when indicated. All results were masked by gray or white matter masks stemming from a segmentation of the average normalized T1s of the participants. The statistical threshold for the hypotheses generating data set from Hamburg was set to cluster-wise FDR-corrected p<0.05 with an entry threshold of voxel-wise uncorrected p<0.001. As no significant results were achieved, the statistical threshold for the data of the two other sites will be set to voxel-wise FWE-corrected p<0.05.
ASL ASL was not yet analyzed for any of the sites. For the statistics we will use Cerebral Perfusion Images stemming from the toolbox ASLtbx (https://www.cfn.upenn.edu/zewang/ASLtbx_manual.pdf). Nevertheless, as different imaging protocols were available in Spain and Italy, a comparison of the equality has to be proofen first. Therefore, we acquired both protocols in the Hamburg data. As we do not expect any differences here, the statistical threshold will be set to voxel-wise FWE-corrected p<0.05.
Power calculation based on Hamburg MR data Power analysis of the primary outcome "prediction of headache reduction with resting-state functional connectivity measures from fMRI of day 1" for which rs-fMRI data of 54 migraine patients from the hypothesis generating site Hamburg were analyzed using the CONN-toolbox revealed that 37 migraine patients are necessary to reproduce the result of significant comodulation in local correlation when corrected for age and gender (80% Power, FWE-corrected p<0.05 calculated with PowerMap). Initial quality checks of the data from the other two sites reveal enough available data for reproduction.
- Conditions
- Migraine
- Being tested
- functional magnetic resonance imaging
- Keywords
- brain morphology, neuronal functional connectivity, CGRP-Antibodies
- Medical subject headings
- Migraine Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
functional magnetic resonance imagingOther
non-diagnostic, non-invasive, passive measurement of the brain\'s structure and function
| Study group | Role | What they receive |
|---|---|---|
| Migraine patients | Not described Receives: Other: functional magnetic resonance imaging | |
| Healthy Controls | Not described Receives: Other: functional magnetic resonance imaging |
What is being measured
The primary outcome is the main question the study is designed to answer.
resting state fMRI
Prediction of reduction in number of headache days at day 1. The statistical threshold will will be set to a small-volume corrected p\<0.05 in the combined data from Barcelona and Pavia.
Measured: 1 year
Morphological MR
Prediction of reduction in number of headache days by gray and white matter density at day 1. The statistical threshold for the data of the two other sites will be set to voxel-wise FWE-corrected p\<0.05.
Measured: 1 year
Arterial Spin Labelling MR
Prediction of reduction in number of headache days by brain perfusion at day 1. ASL was not yet analyzed for any of the sites. For the statistics we will use Cerebral Perfusion Images stemming from the toolbox ASLtbx (https://www.cfn.upenn.edu/zewang/ASLtbx_manual.pdf). The statistical threshold will be set to voxel-wise FWE-corrected p\<0.05.
Measured: 1 year
Secondary outcomes (3)
resting-state fMRI
Comparison of responders and non-responders differences in rs-fMRI functional connectivity, morphometry and perfusion changes at day1. The statistical threshold for the data of the two other sites will be set to voxel-wise FWE-corrected p\<0.05.
Measured: 1 year
Morphological MRI, resting-state fMRI and arterial spin labelling MRI
Comparison of rs-fMRI functional connectivity, morphometry and perfusion changes from day1 and day2. The statistical threshold will be set to voxel-wise FWE corrected p\<0.05.
Measured: 1 year
Morphological MRI, resting-state fMRI and arterial spin labelling MRI
Comparison of rs-fMRI functional connectivity, morphometry and perfusion changes between healthy controls and migraine patients at day1. Significance will be set to a small-volume corrected threshold of p\<0.05 in the combined data from Barcelona and Pavia.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Oct 2024
- Study start15 Jan 2021
- Primary completion1 Mar 2025
- Study completion1 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for MigraineStudies of the same condition, open and under way.
- More trials run by Universitätsklinikum Hamburg-EppendorfThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 219 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06633484
- Sponsor's protocol ID
- BIOMIGA-MR
- Status last verified
- May 2026
- First submitted
- 30 Jul 2024
- Last updated
- 19 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Hougaard A, Gaist D, Garde E, Iversen P, Madsen CG, Kyvik KO, Ashina M, Siebner HR, Madsen KH. Lack of reproducibility of resting-state functional MRI findings in migraine with aura. Cephalalgia. 2023 Nov;43(11):3331024231212574. doi: 10.1177/03331024231212574.
PubMed 37950678Schönthaler, M.G.F., Basedau, H., May, A., Mehnert, J., 2024. Connectivity within the visual cortex predicts the efficacy of CGRP antibodies in migraine patients. DGKN 2024, Frankfurt, Germany and Clinical Neurophysiology 159, e22
Study at a glance
From the registry record, last updated by the sponsor on 19 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- BIOmarkers of MIGraine: a Proof of Concept Study on the Stratification of Responders to CGRP Monoclonal Antibodies - Results From Magnetic Resonance Imaging
- ClinicalTrials.gov ID
- NCT06633484
- Acronym / sponsor ID
- BIOMIGA-MR
- Conditions
- Migraine
- Keywords
- brain morphology, neuronal functional connectivity, CGRP-Antibodies
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 219 participants (estimated)
- Lead sponsor
- Universitätsklinikum Hamburg-EppendorfUniversity, hospital or other
- Study start
- 15 Jan 2021 (actual)
- Primary completion
- 1 Mar 2025 (actual)
- Study completion
- 1 Dec 2026 (estimated)
- First posted
- 9 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The projects comprising in the multicenter BIOMIGA project have been preregistered earlier with ID NTC04503083 at clinicaltrials.gov. Here the imaging subproject within the overall BIOMIGA aims is specified. The hypotheses for this subproject of the magnetic resonance imaging part is based on hypotheses generating analyses of the data from one site (Hamburg, Germany) of this three-center study. At all three sites healthy controls and migraine patients underwent identical protocols with 3 types of magnetic resonance imaging including structural scans (MPRAGE), resting-state functional magnetic resonance imaging (rs-fMRI) as well as arterial spin labeling (ASL) with matched protocols across sites. Data was acquired before CGRP-antibody administration (day 1) and 12 weeks afterwards (day 2). We analyzed the data from one site (Hamburg, Germany) as hypotheses generating, published these data as a poster and aim to validate our results with the not-yet analyzed data from the two other sites (Pavia, Italy and Barcelona, Spain).
Detailed description
The Hamburg data was processed as stated below and will be used as independent data set for hypotheses generation. The data of the two other sites (Italy and Spain) will be processed identically to the Hamburg data set:
rs-FMRI
Preprocessing of the resting-state functional MR data followed the SPM12 pipeline (https://www.fil.ion.ucl.ac.uk/spm/software/spm12/) using slice time correction, realignment, coregistration to the structural image, normalization into MNI space, and smoothing with an 8mm^3 Gausian kernel. Data was further analyzed using the CONN-toolbox (https://web.conn-toolbox.org/) where a 0.003-0.08 Hz temporal filter and denoising with linear regression of confounding effects (white matter, CSF, movement) and linear detrending. We choose:
- Local Homogeneity (LCOR),
- Global Correlations (GCOR),
- Seed-Based Correlations (SBC): Seed to voxel and ROI to ROI with an additional mask of the hypothalamus
- Independent Component Analyses (group-ICA),
- Amplitude of Low-Frequency Fluctuations (ALFF)
Statistical comparisons calculated are defined as primary and secondary outcomes below and include (i) prediction of treatment outcome (reduction in headache days) from T0 (further PR), (ii) alterations between T0 and T1, (iii) differences between healthy controls and migraine patients at T0 (further HvsPAT), and (iv) differences between responders and non-responder at T0 and T1.
In the hypothesis generating Hamburg data significant results at a threshold of cluster-wise FDR-corrected p<0.05 with an entry threshold of voxel-wise uncorrected p<0.001, when corrected for age and sex in were found:
- LCOR: PR: Two clusters in left lateral occipital cortex and right temporal fusiform cortex; HvsPAT: bilateral thalamus left frontal operculum.
- SBC Seed to Voxel: PR: Hypothalamus 2 clusters, Sensori Motor Lateral R 1 cluster, Visula Lateral L 1 cluster, Visual Lateral R 3 cluster; HvsPAT: Sensori Motor Lateral L 5 cluster, Sensori Motor Lateral R 1 cluster, Sensori Motor Superior 3 cluster, Visual Medial 3 cluster, Visual Occipital 1 cluster, Visual Lateral L 4 cluster, Visual Lateral R 1 cluster,
- ICA: ICA 5 2 cluster, ICA 16 2 cluster, ICA 28 1 cluster, ICA 34 2 cluster; HvsPAT: ICA 4 3cluster, ICA 6 4 cluster, ICA 14 4 cluster, ICA 18 2 cluster, ICA 27 3 cluster, ICA 29 14 cluster, ICA 33 3 cluster, ICA 36 7 cluster, ICA 38 6 cluster
- There were no significant results for SBC ROI to ROI, GCOR and ALFF
- There were no significant results for the chosen threshold for the comparisons between responders and non-responder at T0 and T1 Preliminary results for local and global connectivity were recently presented at a scientific conference.
To reproduce the significant results from the Hamburg data there is choosen a small volume-corrected threshold of p<0.05. For non-significant result, the statistical threshold for the data of the two other sites will be set to voxel-wise FWE-corrected p<0.05.
MPRAGE Raw T1-images (aka MPRAGE) were processed using the CAT12-toolbox (https://neuro-jena.github.io/cat12-help/) which extents SPM12 (https://www.fil.ion.ucl.ac.uk/spm/software/spm12/). For controls and migraine patients with data from only the first day, images segmented into compartments of gray and white matter and normalized. For patients with data from 2 days, data was longitudinally segmented. Images of gray and white matter were smoothed with an isotropic Gaussian kernel of 6 mm3. T-test and F-tests implemented in the SPM12 toolbox were used to estimate significant differences at a threshold of cluster-wise-correct p<0.05. The individual total intracranial volume (TIV), which is also estimated by the CAT12-toolbox, was used as covariate to control for different brain sizes. Age and gender were used as further covariates when indicated. All results were masked by gray or white matter masks stemming from a segmentation of the average normalized T1s of the participants. The statistical threshold for the hypotheses generating data set from Hamburg was set to cluster-wise FDR-corrected p<0.05 with an entry threshold of voxel-wise uncorrected p<0.001. As no significant results were achieved, the statistical threshold for the data of the two other sites will be set to voxel-wise FWE-corrected p<0.05.
ASL ASL was not yet analyzed for any of the sites. For the statistics we will use Cerebral Perfusion Images stemming from the toolbox ASLtbx (https://www.cfn.upenn.edu/zewang/ASLtbx_manual.pdf). Nevertheless, as different imaging protocols were available in Spain and Italy, a comparison of the equality has to be proofen first. Therefore, we acquired both protocols in the Hamburg data. As we do not expect any differences here, the statistical threshold will be set to voxel-wise FWE-corrected p<0.05.
Power calculation based on Hamburg MR data Power analysis of the primary outcome "prediction of headache reduction with resting-state functional connectivity measures from fMRI of day 1" for which rs-fMRI data of 54 migraine patients from the hypothesis generating site Hamburg were analyzed using the CONN-toolbox revealed that 37 migraine patients are necessary to reproduce the result of significant comodulation in local correlation when corrected for age and gender (80% Power, FWE-corrected p<0.05 calculated with PowerMap). Initial quality checks of the data from the other two sites reveal enough available data for reproduction.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Migraine patients | – | Other: functional magnetic resonance imaging |
| Healthy Controls | – | Other: functional magnetic resonance imaging |
Who may qualify
- Ages
- 25 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Migraine patients and Healthy controls. The healthy controls where recruited among hospital staff and non-related acquaintances of the patients. All migraine patients enrolled in the study have been treated with CGRP-targeting mABs according to the indications approved by the respective National regulatory bodies(Germany, Spain, Italy).
Key inclusion criteria (7 listed)
- Migraine patients
- Adults between 25 and 55 years of age of both sexes;
- Patients diagnosed with high-frequency migraine (HFM) 8 or more migraine days/month) or CM with or without aura (>15 headache days migraine/month, of which 8 have migraine characteristics) according to the International Classification of Headache Disorders, 3rd edition, (ICHD-3);
- Females had to be postmenopausal for at least one year, surgically sterile or otherwise incapable of pregnancy, or using an acceptable method of birth control.
- Healthy controls
Key exclusion criteria (9 listed)
- Headache on more than 25 days/month in the last 3 months;
- Medication overuse according to the ICHD-3 criteria.
- For the entire study population (migraine and healthy controls)
- Presence of any other significant medical condition (neurological disorders, severe psychiatric illness or cardiovascular disease);
- Evidence of drug, smoking or alcohol abuse or dependence within 12 months prior to V1, based on medical records or patient self-report. An alcohol consumption >100g/week will be considered as an abuse;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| functional magnetic resonance imagingnon-diagnostic, non-invasive, passive measurement of the brain\'s structure and function | Other | Healthy Controls, Migraine patients |
Primary outcome
resting state fMRI
Time frame: 1 year
Prediction of reduction in number of headache days at day 1. The statistical threshold will will be set to a small-volume corrected p\<0.05 in the combined data from Barcelona and Pavia.
Morphological MR
Time frame: 1 year
Prediction of reduction in number of headache days by gray and white matter density at day 1. The statistical threshold for the data of the two other sites will be set to voxel-wise FWE-corrected p\<0.05.
Arterial Spin Labelling MR
Time frame: 1 year
Prediction of reduction in number of headache days by brain perfusion at day 1. ASL was not yet analyzed for any of the sites. For the statistics we will use Cerebral Perfusion Images stemming from the toolbox ASLtbx (https://www.cfn.upenn.edu/zewang/ASLtbx_manual.pdf). The statistical threshold will be set to voxel-wise FWE-corrected p\<0.05.
3 secondary outcomes
resting-state fMRI
Time frame: 1 year
Morphological MRI, resting-state fMRI and arterial spin labelling MRI
Time frame: 1 year
Morphological MRI, resting-state fMRI and arterial spin labelling MRI
Time frame: 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 May 2026.
- Background: PubMed 37950678Hougaard A, Gaist D, Garde E, Iversen P, Madsen CG, Kyvik KO, Ashina M, Siebner HR, Madsen KH. Lack of reproducibility of resting-state functional MRI findings in migraine with aura. Cephalalgia. 2023 Nov;43(11):3331024231212574. doi: 10.1177/03331024231212574.
- BackgroundSchönthaler, M.G.F., Basedau, H., May, A., Mehnert, J., 2024. Connectivity within the visual cortex predicts the efficacy of CGRP antibodies in migraine patients. DGKN 2024, Frankfurt, Germany and Clinical Neurophysiology 159, e22
- SPM12: Toolbox for preprocessing of (f)MRI dataLink provided by the sponsor.
- CONN: Toolbox for analysis of resting-state fMRI dataLink provided by the sponsor.
- CAT12: Toolbox for analysis of structural MRI data (MPRAGE/T1)Link provided by the sponsor.
- ASLtbx: Toolbox for analysis of aterial-spin-labellingMRI dataLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Migraine
RecruitingObservational study
Study of the Glymphatic System in Migraine
Migraine
Active, not recruiting
Clinical and Neurophysiological Effects of tDCS to Visual and Motor Cortex in Migraine
Migraine
Active, not recruiting
App-Based Migraine Treatment: The Health enSuite Study
Migraine, Migraine With Aura
Not yet recruiting
A Prospective Study of Rimegepant for Short-term Preventive Treatment of Night-shift-related Migraine in Healthcare Professionals
Migraine Disorders
Recruiting
Marine Lipids Ease Painful TMD
Temporomandibular Disorder (TMD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
3 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Migraine, run by Universitätsklinikum Hamburg-Eppendorf at 3 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 19 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Germany, Italy, Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
resting state fMRI (time frame: 1 year). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06633484, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 May 2026.